107 related articles for article (PubMed ID: 30522598)
1. Association Between Pancreatic Cancer and Dipeptidyl Peptidase-4 Inhibitors Use in a Case-Control Study.
Lai SW; Lin CL; Liao KF
Mayo Clin Proc; 2018 Dec; 93(12):1874-1876. PubMed ID: 30522598
[No Abstract] [Full Text] [Related]
2. ACP Journal Club. Review: in type 2 diabetes, dipeptidyl peptidase-4 inhibitors do not increase pancreatitis.
Morey-Vargas OL; Montori VM
Ann Intern Med; 2014 Jan; 160(2):JC8-9. PubMed ID: 24445718
[No Abstract] [Full Text] [Related]
3. Incretin based drugs and the risk of pancreatic cancer: international multicentre cohort study.
Azoulay L; Filion KB; Platt RW; Dahl M; Dormuth CR; Clemens KK; Durand M; Juurlink DN; Targownik LE; Turin TC; Paterson JM; Ernst P;
BMJ; 2016 Feb; 352():i581. PubMed ID: 26888382
[TBL] [Abstract][Full Text] [Related]
4. Incretin-based therapies and risk of pancreatic cancer in patients with type 2 diabetes: A meta-analysis of randomized controlled trials.
Wang H; Liu Y; Tian Q; Yang J; Lu R; Zhan S; Haukka J; Hong T
Diabetes Obes Metab; 2018 Apr; 20(4):910-920. PubMed ID: 29193572
[TBL] [Abstract][Full Text] [Related]
5. Incretin-based glucose-lowering medications and the risk of acute pancreatitis and/or pancreatic cancer: Reassuring data from cardio-vascular outcome trials.
Nauck MA; Meier JJ; Schmidt WE
Diabetes Obes Metab; 2017 Sep; 19(9):1327-1328. PubMed ID: 28432752
[No Abstract] [Full Text] [Related]
6. Association Between Use of Dipeptidyl Peptidase-4 Inhibitors and the Risk of Acute Kidney Injury: A Nested Case-Control Study.
Shih CJ; Lee YJ; Lo YH; Kuo SC; Ou SM; Chen YT
Mayo Clin Proc; 2016 Jul; 91(7):867-72. PubMed ID: 27236426
[TBL] [Abstract][Full Text] [Related]
7. Dipeptidyl peptidase-4 inhibitor decreases the risk of atrial fibrillation in patients with type 2 diabetes: a nationwide cohort study in Taiwan.
Chang CY; Yeh YH; Chan YH; Liu JR; Chang SH; Lee HF; Wu LS; Yen KC; Kuo CT; See LC
Cardiovasc Diabetol; 2017 Dec; 16(1):159. PubMed ID: 29258504
[TBL] [Abstract][Full Text] [Related]
8. The safety of incretin based drug treatments for type 2 diabetes.
Bolen SD; Maruthur NM
BMJ; 2016 Feb; 352():i801. PubMed ID: 26888024
[No Abstract] [Full Text] [Related]
9. Pro- or anti-inflammatory properties of the adipokine dipeptidyl peptidase-4?
Xu L; Spinas GA; Niessen M
Gastroenterology; 2011 Dec; 141(6):e17. PubMed ID: 22036848
[No Abstract] [Full Text] [Related]
10. Dipeptidyl Peptidase-4 Inhibitors and Risk of Heart Failure in Patients With Type 2 Diabetes Mellitus: A Population-Based Cohort Study.
Kim YG; Yoon D; Park S; Han SJ; Kim DJ; Lee KW; Park RW; Kim HJ
Circ Heart Fail; 2017 Sep; 10(9):. PubMed ID: 28899989
[TBL] [Abstract][Full Text] [Related]
11. Potential linkage between dipeptidyl peptidase-4 inhibitor use and the risk of pancreatitis/pancreatic cancer.
Shirakawa J; Terauchi Y
J Diabetes Investig; 2020 Jul; 11(4):789-791. PubMed ID: 31774618
[No Abstract] [Full Text] [Related]
12. Association between use of oral-antidiabetic drugs and the risk of aortic aneurysm: a nested case-control analysis.
Hsu CY; Su YW; Chen YT; Tsai SH; Chang CC; Li SY; Huang PH; Chen JW; Lin SJ
Cardiovasc Diabetol; 2016 Sep; 15(1):125. PubMed ID: 27585542
[TBL] [Abstract][Full Text] [Related]
13. Incidence of pancreatitis and pancreatic cancer in a randomized controlled multicenter trial (SAVOR-TIMI 53) of the dipeptidyl peptidase-4 inhibitor saxagliptin.
Raz I; Bhatt DL; Hirshberg B; Mosenzon O; Scirica BM; Umez-Eronini A; Im K; Stahre C; Buskila A; Iqbal N; Greenberger N; Lerch MM
Diabetes Care; 2014 Sep; 37(9):2435-41. PubMed ID: 24914244
[TBL] [Abstract][Full Text] [Related]
14. Incretin-based pharmacotherapy and risk of adverse pancreatic events in the ethnic Chinese with diabetes mellitus: A population-based study in Taiwan.
Tseng CM; Liao WC; Chang CY; Lee CT; Tseng CH; Hsu YC; Lin JT
Pancreatology; 2017; 17(1):76-82. PubMed ID: 27743712
[TBL] [Abstract][Full Text] [Related]
15. Dipeptidyl Peptidase-4 Inhibitor-Associated Pancreatic Carcinoma: A Review of the FAERS Database.
Nagel AK; Ahmed-Sarwar N; Werner PM; Cipriano GC; Van Manen RP; Brown JE
Ann Pharmacother; 2016 Jan; 50(1):27-31. PubMed ID: 26497885
[TBL] [Abstract][Full Text] [Related]
16. Cardiovascular Outcomes of Dipeptidyl Peptidase-4 Inhibitors in Elderly Patients With Type 2 Diabetes: A Nationwide Study.
Shih CJ; Chen HT; Kuo SC; Ou SM; Chen YT
J Am Med Dir Assoc; 2016 Jan; 17(1):59-64. PubMed ID: 26612484
[TBL] [Abstract][Full Text] [Related]
17. Dipeptidyl peptidase-4 inhibitors and the risk of community-acquired pneumonia in patients with type 2 diabetes.
Faillie JL; Filion KB; Patenaude V; Ernst P; Azoulay L
Diabetes Obes Metab; 2015 Apr; 17(4):379-85. PubMed ID: 25581902
[TBL] [Abstract][Full Text] [Related]
18. Antihyperglycemic drugs use and new-onset atrial fibrillation in elderly patients.
Chen HY; Yang FY; Jong GP; Liou YS
Eur J Clin Invest; 2017 May; 47(5):388-393. PubMed ID: 28369870
[TBL] [Abstract][Full Text] [Related]
19. Dipeptidyl peptidase IV inhibitors, a risk factor for bullous pemphigoid: Retrospective multicenter case-control study from France and Switzerland.
Benzaquen M; Borradori L; Berbis P; Cazzaniga S; Valero R; Richard MA; Feldmeyer L
J Am Acad Dermatol; 2018 Jun; 78(6):1090-1096. PubMed ID: 29274348
[TBL] [Abstract][Full Text] [Related]
20. Dipeptidyl peptidase-4 inhibitor treatment could decrease chronic rhinosinusitis in diabetic patients.
Li SY; Chen HH; Lai CC; Lin CL; Kao CH
QJM; 2020 Mar; 113(3):181-185. PubMed ID: 31584671
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
